Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.21.73 (urokinase-type plasminogen activator)
 10,685 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

All the malignant tumors possess the same characteristic to form distant secondary tumors or metastasis. The acquisition of the metastatic potential takes place in random accumulation of different genetic and cellular changes. Their combination allows one or several tumor cells to achieve the whole metastatic process. The metastatic process involves numerous interactions between the tumor cells and the host cells of the tumor cells and the extracellular matrix. The attachment of the metastatic cells to the extracellular matrix specific glycoproteins involves cell surface receptors as integrins, sialyled residues or CD44. On the other hand, other adhesive molecules (Cadherins) display inhibitory action on the metastatic process. The enzymatic lysis is carried out by glycolytic enzymes and proteases: metalloproteases (inhibitors TIMP1 et TIMP2), serine proteases (tPA, uPA-inhibitors: PAI1 and PAI2). Cathepsin D or Heparanases. Several enzymes may be necessary for the degradation of the basal membrane. The crossing of both basal membrane and stroma can be made on account of the cell motility. Some factors can modify this property as AMF (Autocrin Motility Factor) or ATX (Autotoxin) but the molecular mechanisms involved in the migration are not yet completely understood. The last stage is relative to the cells proliferation in the site organ; it depends on autocrine (CSF1, IL2, Bombesine...) or some paracrine growth factors. However, the formation of metastasis is possible only in the site organ attaching the cells.
 ...
PMID:[The metastatic process]. 770 63

We have produced an Fc conjugate of colony-stimulating factor (CSF) 1 with an improved circulating half-life. CSF1-Fc retained its macrophage growth-promoting activity, and did not induce proinflammatory cytokines in vitro. Treatment with CSF1-Fc did not produce adverse effects in mice or pigs. The impact of CSF1-Fc was examined using the Csf1r-enhanced green fluorescent protein (EGFP) reporter gene in MacGreen mice. Administration of CSF1-Fc to mice drove extensive infiltration of all tissues by Csf1r-EGFP positive macrophages. The main consequence was hepatosplenomegaly, associated with proliferation of hepatocytes. Expression profiles of the liver indicated that infiltrating macrophages produced candidate mediators of hepatocyte proliferation including urokinase, tumor necrosis factor, and interleukin 6. CSF1-Fc also promoted osteoclastogenesis and produced pleiotropic effects on other organ systems, notably the testis, where CSF1-dependent macrophages have been implicated in homeostasis. However, it did not affect other putative CSF1 targets, notably intestine, where Paneth cell numbers and villus architecture were unchanged. CSF1 has therapeutic potential in regenerative medicine in multiple organs. We suggest that the CSF1-Fc conjugate retains this potential, and may permit daily delivery by injection rather than continuous infusion required for the core molecule.
...
PMID:Characterisation of a novel Fc conjugate of macrophage colony-stimulating factor. 2518 60